H.(T.) v. Novartis Pharm. Corp.

371 P.3d 241, 203 Cal. Rptr. 3d 22
California Supreme Court·Decided June 8, 2016·No. No. S233898.·Published·Cited by 1 cases

Opinion

The applications to appear as counsel pro hac vice are granted. The petition for review is granted. The issue to be briefed and argued is limited to the following: May the brand name manufacturer of a pharmaceutical drug that divested all ownership interest in the drug be held liable for injuries caused years later by another manufacturer's generic version of that drug?

WERDEGAR, J., was recused and did not participate.

Free access — add to your briefcase to read the full text and ask questions with AI

H.(T.) v. Novartis Pharm. Corp., 371 P.3d 241, 203 Cal. Rptr. 3d 22 (Cal. 2016).

371 P.3d 241 (H.(T.) v. Novartis Pharm. Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

McNair v. Johnson & Johnson
694 F. App'x 115 (Fourth Circuit, 2017)